anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Imatinib Mesylate
Trial phase: Phase 2
SMILES: CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
Eligibility criteria:
DISEASE CHARACTERISTICS:

Diagnosis of myelofibrosis with myeloid metaplasia (MMM), defined by all of the following:

Leukoerythroblastic blood picture
Fibrosis involving > 1/3 sectional area of bone marrow biopsy
Splenomegaly (unless patient has undergone prior splenectomy)
Philadelphia chromosome negative
No myelodysplastic syndrome
No systemic disorders associated with marrow fibrosis

Red blood cell transfusion dependent, defined by 1 of the following:

Patient has required ≥ 2 units of red blood cells every 4 weeks within the past 8 weeks
Hemoglobin ≤ 8 g/dL on ≥ 3 occasions (≥ 2 weeks apart ) over the past 8 weeks
No evidence of disease transformation to acute myelogenous leukemia, defined as > 20% blasts in bone marrow and/or peripheral blood

PATIENT CHARACTERISTICS:

Performance status

ECOG 0-3

Life expectancy

Not specified

Hematopoietic

Absolute neutrophil count > 1,000/mm^3
Platelet count > 50,000/mm^3

Hepatic

Bilirubin ≤ 1.5 times upper limit of normal (ULN)
AST or ALT ≤ 2 times ULN (unless due to extramedullary hematopoiesis in the liver)

Renal

Creatinine ≤ 1.5 times ULN

Cardiovascular

No New York Heart Association grade III-IV heart disease

Other

Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective barrier method contraception during and for 3 months after completion of study treatment
No serious, uncontrolled medical condition
No patients who are considered potentially unreliable or with a history of noncompliance to medical regimens

PRIOR CONCURRENT THERAPY:

Biologic therapy

More than 2 weeks since prior interferon alfa

Chemotherapy

No concurrent chemotherapy except hydroxyurea to control elevated blood counts

Endocrine therapy

More than 4 weeks since prior corticosteroids, danazol, or other androgens for MMM

Other

More than 4 weeks since other prior treatment for MMM
No other concurrent experimental drug therapy for MMM
Intervention: Isoflavone
Trial phase: Phase 4
SMILES: O=c1c(-c2ccccc2)coc2ccccc12
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 39
Group description: Isoflavone

Isoflavone
Eligibility criteria:
Inclusion Criteria:

men > or =21 with prostate CA and hypogonadism for at least 3 months

Exclusion Criteria:

on growth promoting agents
on appetite stimulating agents
on Prednisone and others
Intervention: DABIGATRAN ETEXILATE
Trial phase: Phase 2
ATC code: B01AE07
SMILES: CCCCCCOC(=O)NC(=N)c1ccc(NCc2nc3cc(C(=O)N(CCC(=O)OCC)c4ccccn4)ccc3n2C)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 133
Group description: Patients were treated with 110mg dabigatran etexilate once daily.
Eligibility criteria:
Inclusion criteria Inclusion criteria

Patients scheduled to undergo a primary, unilateral elective total knee replacement
Male or Female 20 years of age or order
Patients weighing at least 40 kg
Written informed consent prior to the start of study participation

Exclusion criteria Exclusion criteria

History of bleeding diathesis
Constitutional or acquired coagulation disorders that in the investigator's judgment puts the patient at excessive risk for bleeding
Major surgery or trauma (e.g. hip fracture) within the last 3 months
Recent unstable cardiovascular disease, such as uncontrolled hypertension at the time of enrollment (investigator's judgment) or history of myocardial infarction within the last 3 months
Any history of hemorrhagic stroke or any of the following intracranial pathologies: bleeding, neoplasm, AV (arteriovenous) malformation or aneurysm or recent bleeding history
Condition requiring anti-coagulant therapy
Elevated AST(Aspartate Aminotransferase) , ALT(Alanine Aminotransferase), or any history of clinically relevant liver disease
Patients with a history of clinically significant renal diseases or with elevated creatinine values
Intervention: Telcagepant
Trial phase: Phase 2
SMILES: O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 17
Group description: MK0974 25 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
Eligibility criteria:
Inclusion Criteria:

Patient has at least 1 year history of migraine (with or without aura)
Females of childbearing years must use acceptable contraception throughout trial
Patient is in general good health based on screening assessment

Exclusion Criteria:

Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)
Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease
Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)
Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption
Patient has a history of cancer within the last 5 years
Intervention: Telcagepant
Trial phase: Phase 2
SMILES: O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: MK0974 50 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
Eligibility criteria:
Inclusion Criteria:

Patient has at least 1 year history of migraine (with or without aura)
Females of childbearing years must use acceptable contraception throughout trial
Patient is in general good health based on screening assessment

Exclusion Criteria:

Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)
Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease
Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)
Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption
Patient has a history of cancer within the last 5 years
Intervention: Telcagepant
Trial phase: Phase 2
SMILES: O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 27
Group description: MK0974 100 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
Eligibility criteria:
Inclusion Criteria:

Patient has at least 1 year history of migraine (with or without aura)
Females of childbearing years must use acceptable contraception throughout trial
Patient is in general good health based on screening assessment

Exclusion Criteria:

Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)
Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease
Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)
Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption
Patient has a history of cancer within the last 5 years
Intervention: Telcagepant
Trial phase: Phase 2
SMILES: O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: MK0974 200 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
Eligibility criteria:
Inclusion Criteria:

Patient has at least 1 year history of migraine (with or without aura)
Females of childbearing years must use acceptable contraception throughout trial
Patient is in general good health based on screening assessment

Exclusion Criteria:

Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)
Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease
Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)
Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption
Patient has a history of cancer within the last 5 years
Intervention: Telcagepant
Trial phase: Phase 2
SMILES: O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 51
Group description: MK0974 300 mg; one orally-administered dose, plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
Eligibility criteria:
Inclusion Criteria:

Patient has at least 1 year history of migraine (with or without aura)
Females of childbearing years must use acceptable contraception throughout trial
Patient is in general good health based on screening assessment

Exclusion Criteria:

Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)
Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease
Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)
Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption
Patient has a history of cancer within the last 5 years
Intervention: Telcagepant
Trial phase: Phase 2
SMILES: O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 52
Group description: MK0974 400 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
Eligibility criteria:
Inclusion Criteria:

Patient has at least 1 year history of migraine (with or without aura)
Females of childbearing years must use acceptable contraception throughout trial
Patient is in general good health based on screening assessment

Exclusion Criteria:

Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)
Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease
Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)
Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption
Patient has a history of cancer within the last 5 years
Intervention: Telcagepant
Trial phase: Phase 2
SMILES: O=C(N[C@@H]1CC[C@@H](c2cccc(F)c2F)CN(CC(F)(F)F)C1=O)N1CCC(n2c(=O)[nH]c3ncccc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 49
Group description: MK0974 600 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
Eligibility criteria:
Inclusion Criteria:

Patient has at least 1 year history of migraine (with or without aura)
Females of childbearing years must use acceptable contraception throughout trial
Patient is in general good health based on screening assessment

Exclusion Criteria:

Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)
Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease
Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)
Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption
Patient has a history of cancer within the last 5 years
Intervention: Rizatriptan
Trial phase: Phase 2
ATC code: N02CC04
SMILES: CN(C)CCc1c[nH]c2ccc(Cn3cncn3)cc12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 50
Group description: Rizatriptan 10 mg; one orally-administered dose plus an optional second dose (placebo) to treat a single moderate-to-severe migraine headache.
Eligibility criteria:
Inclusion Criteria:

Patient has at least 1 year history of migraine (with or without aura)
Females of childbearing years must use acceptable contraception throughout trial
Patient is in general good health based on screening assessment

Exclusion Criteria:

Patient is pregnant/breast-feeding (or is a female expecting to conceive during the study period)
Patient has heart disease, uncontrolled hypertension (high blood pressure), uncontrolled diabetes or other significant disease
Patient has major depression, other pain syndromes that might interfere with study assessments, psychiatric conditions, dementia, or significant neurological disorders (other then migraine)
Patient has a history of gastric or small intestinal surgery or has a disease that causes malabsorption
Patient has a history of cancer within the last 5 years
Intervention: Paroxetine
Trial phase: Phase 4
ATC code: N06AB05
SMILES: Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Paroxetine

Paroxetine: 16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
Eligibility criteria:
Inclusion Criteria:

Meets DSM-IV criteria for current social anxiety disorder
Reports social anxiety in most situations (generalized type).
Treatment seeking for relief of social anxiety.
Meets DSM-IV criteria for current alcohol use disorder
Reads at the 6th grade level or above
Endorses using alcohol to cope with social anxiety either "very often" or "always."
Reports no prior medical alcohol detoxification
Willingness to be randomized to the placebo group
Willingness to attend 16 weekly medication management visits and one alcohol-related therapy session
Liebowitz Social Anxiety Scale Total score (modified version) of at least 60
Endorses drinking at least 15 standard drinks in a typical 30 day period or reports drinking heavily (defined as greater-than-or-equal-to 4 standard drinks on one occasion for women; greater-than-or-equal-to 5 standard drinks on one occasion for men, respectively) on at least 2 days in a typical 30 day period.

Exclusion Criteria:

Abuse or dependence on drugs other than nicotine or marijuana in last 90 days
Current or past diagnosis of bipolar disorder or schizophrenia
Significant suicide risk as assessed by the SCID
Current use of psychotropic medications
Treatment seeking for alcohol problems
Any unstable medical condition that might interfere with safe participation in the trial
Elevated liver enzymes (3 x greater than normal levels)
History of adverse reaction to paroxetine
History of failure to respond to adequate trial or dose of paroxetine for social phobia (60 mg/day for at least 6 weeks)
History of heart problems or abnormal ECG recording
Pregnancy, nursing, or refusal to use effective birth control if sexually active and premenopausal
History of one or more alcohol detoxifications
Intervention: Doxycycline
Trial phase: Phase 2
ATC code: A01AB22 | J01AA02 | J01AA20
SMILES: [H][C@@]12C(=C(O)[C@]3(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]3([H])[C@H]1O)C(=O)c1c(O)cccc1[C@@H]2C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 56
Group description: Patients received oral administration of 20 mg of doxycycline, twice a day at least 2 days prior to surgery, on the day of surgery, and for the first 3 postoperative days (via a nasogastric tube or orally when patients tolerated it).

Periostat: In addition to standard care, patients received oral administration of 20 mg of doxycycline twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
Eligibility criteria:
Inclusion Criteria:

Written informed consent
Aged 18 through 80 years, inclusive
Scheduled for primary CABG surgery with CPB

Exclusion Criteria:

Females of childbearing potential
Emergency CABG
Previous sternotomy
Planned simultaneous surgery (i.e. valve repair or carotid endarterectomy)
Myocardial infarction within 48 hours
Pre-operative atrial fibrillation
Pre-operative ventricular pacing or left bundle branch block (LBBB)
Known hypersensitivity to tetracycline class antibiotics
Renal failure requiring dialysis
Intervention: Acetylcysteine
Trial phase: Phase 3
ATC code: R05CB01 | S01XA08 | V03AB23
SMILES: CC(=O)N[C@@H](CS)C(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 92
Group description: Eligible children were adaptively allocated by age (less than 2 years of age or at least 2 years old) and HE (grade 0-1 or 2-4) to receive NAC (150 mg/kg/d) in 5% dextrose (D5W) infused over 24 hours for up to 7 consecutive days

N-acetylcysteine: The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
Eligibility criteria:
Inclusion Criteria:

Meet entry criteria for and be enrolled in the Pediatric Acute Liver Failure prospective database.
Able to be evaluated and initiate treatment within the first 24 hours of hospitalization
Patients transferred from referring hospitals to the study site may be considered for enrollment, provided that no other treatment protocol has begun, and that no liver support device (BAL, extracorporeal liver assist device, transgenic pig perfusion) has been used or is contemplated.
Use of fresh frozen plasma infusions will not disqualify patients from participation.

Exclusion Criteria:

older than 18 years of age
pregnancy
ALF that is secondary to acute acetaminophen toxicity, mushroom poisoning, or a known malignancy.
Patients who exhibit signs of cerebral herniation, have intractable arterial hypotension, require inotropic drugs, or demonstrate signs of sepsis (temperature ≥ 39.5o C or bacteremia) at the time of enrollment
No exclusion will be made on the basis of race, ethnic group or gender.
Criteria for inclusion of females and minorities will be those established in the NIH guidelines
Intervention: Citalopram
Trial phase: Phase 2 | Phase 3
ATC code: N06AB04 | N06AB10
SMILES: CN(C)CCCC1(c2ccc(F)cc2)OCc2cc(C#N)ccc21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 98
Group description: Escitalopram tablet (10 mg) plus a placebo amitriptyline capsule will be taken by mouth at night half an hour before bedtime for 12 weeks.
Eligibility criteria:
Inclusion Criteria:

Normal esophagogastroduodenoscopy (EGD) (no esophagitis, Barrett's esophagus, cancer, erosions, or ulcer disease) within the past 5 years
Diagnosis of functional dyspepsia
Patients may have failed to adequately respond to antisecretory therapy in the past for functional dyspepsia to be suitable; a good response to antisecretory therapy, which remains first line therapy, suggests underlying gastroesophageal reflux disease (GERD).

Exclusion Criteria:

Any documented history of endoscopic esophagitis, or predominant heartburn or acid regurgitation, or these symptoms two or more times per week in the prior year, to exclude GERD.
Those who have had an adequate response to antisecretory therapy according to the physician interview, to exclude patients with disease easy to control with first line therapy or misdiagnosed GERD.
Any documented peptic ulcer disease.
Regular use of non-steroidal anti-inflammatory drugs (except long term low dose aspirin ≤ 325 mg / day)
Subjects undergoing psychiatric treatment, having a current history of drug or alcohol abuse, or currently taking psychotropic medication for depression or psychosis, or eating disorders
A history of abdominal surgery except appendectomy, cholecystectomy or hysterectomy, tubal ligations, bladder slings, and vasectomies
Subjects with concurrent major physical illness (including cardiac or liver disease, diabetes, inflammatory bowel disease, glaucoma, urinary retention, active thyroid disease, vasculitis, lactose intolerance explaining symptoms)
Subjects whose literacy skills are insufficient to complete self report questionnaires.
Pregnancy, or refusal to apply adequate contraceptive measures during the trial
Subjects currently on antidepressant therapy will be excluded.
Patients who score 11 or greater on the 7 questions related to depression of the Hospital Anxiety Depression Scale will be excluded. These patients will be encouraged to get follow up for depression.
All eligible patients over age 50 will have an EKG before randomization. Those found to have significant arrhythmias, conduction defects or a previous myocardial infarction on EKG will be excluded. Anyone with QT prolongation will be excluded.

The following concomitant medications will be prohibited during the trial:

Systemically acting cholinergics and anticholinergics (atropine, didinium bromide, propantheline)
Prokinetics (e.g., metoclopramide, tegaserod)
Macrolide antibiotics (e.g., erythromycin, azithromycin)
Aspirin (> 325 mg/day)
Spasmolytics (e.g., dicyclomine)
Antidepressants other than study medications
Serotonin enhancing drugs: monamine oxidase inhibitors, anticonvulsants, dextromethorphan.

Participants will be instructed to avoid grapefruit/grapefruit juice during the trial.
Intervention: FOLIC ACID
Trial phase: Phase 4
ATC code: B03AD01 | B03AD02 | B03AD03 | B03AD04 | B03AD05 | B03AE01 | B03AE02 | B03BB01 | B03BB51 | V04CX02
SMILES: Nc1nc(=O)c2nc(CNc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc3)cnc2[nH]1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 46
Group description: Participants receiving 2 mg/daily of folate, for 12 weeks
Eligibility criteria:
Inclusion Criteria:

Schizophrenia, any subtype
Ages 18-68
Male or female
A score at least a 3 (moderate or greater severity) on at least one of the SANS global assessment subscales, with the exception of the attention global assessment subscale
Stable antipsychotic dose for > 6 weeks
Capable of providing informed consent

Exclusion Criteria:

Unstable medical illness
Substance abuse
Megaloblastic anemia
Non-english speaking
Intervention: Acamprosate
Trial phase: Phase 4
ATC code: N07BB03
SMILES: CC(=O)NCCCS(=O)(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 26
Group description: Criminal justice supervisees given acamprosate for alcohol dependence
Eligibility criteria:
Inclusion Criteria:

History of alcohol dependence in the year before entering criminal justice supervision
Currently under criminal justice supervision (drug court, probation, or parole) in central Virginia

Exclusion Criteria:

Pregnant or nursing a baby
Known sensitivity to acamprosate
Elevated serum creatinine level or other evidence of kidney problems
Symptoms of severe depression or suicidal ideation
Non-English speaking such that they cannot provide informed consent
Cognitive impairment such that they cannot provide informed consent